Supplemental material
Open access
2,220
Views
27
CrossRef citations to date
0
Altmetric
Original Research
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis
Lorcan McGarveyCentre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United KingdomCorrespondence[email protected]
, Dennis NiewoehnerMinneapolis VA Health Care System, Minneapolis, Minnesota, USA
, Sheldon MagderMcGill University Health Centre, Montreal, Canada
, Paul SachsPulmonary Associates of Stamford, Stamford, Connecticut, USA
, Kay TetzlaffBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany;Department of Sports Medicine, Medical Clinic V, University of Tübingen, Tübingen, Germany
, Alan HamiltonBoehringer Ingelheim, Burlington, Ontario, Canada
, Lawrence KorduckiBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA
, Ulrich BothnerBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
, Claus VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Germany
, Andrea KochMedical Clinic III for Pneumology, Allergology, Sleep and Respiratory Medicine, University Hospital Bochum-Bergmannsheil, Bochum, Germany
& Gary T. FergusonPulmonary Research Institute of Southeast Michigan, Livonia, Michigan, USA
show all
Pages 484-493
|
Published online: 18 Feb 2015
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.